[
    {
        "id": "osp-10093",
        "type": "article-journal",
        "title": "Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus: An open-label comparative study",
        "author": [
            {
                "family": "Sharma",
                "given": "Vikram"
            },
            {
                "family": "Chawla",
                "given": "Shalini"
            },
            {
                "family": "Garg",
                "given": "Sandeep"
            },
            {
                "family": "Singh",
                "given": "Bhupinder"
            }
        ],
        "URL": "https://omanscience.com/ar/articles/efficacy-and-safety-of-vildagliptin-and-remogliflozin-as-add-on-therapy-to-metformin-in-patients-of-type-2-diabetes-mellitus-an-open-label-comparative",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2025
                ]
            ]
        },
        "container-title": "Sultan Qaboos University Medical Journal",
        "volume": "24",
        "issue": "2",
        "page": "243-249",
        "DOI": "10.18295/squmj.1.2024.006",
        "publisher": "Sultan Qaboos University",
        "ISSN": "2075-051X",
        "abstract": "Objectives: This study aimed to evaluate the safety and efficacy of remogliflozin compared to vildagliptin as an add-on drug to metformin in type 2 diabetes mellitus (T2DM) treatment. Metformin is considered a first-line drug in T2DM. However, as the disease progresses with heightened insulin resistance and declining β-cell function, the use of metformin alone is often inadequate to achieve optimum glucose levels. Methods: This prospective, randomised study was conducted at Maulana Azad Medical College and Associated Hospital in New Delhi, India, between February 2020 to January 2021. This study recruited 60 T2DM patients aged 35–70 years with glycated haemoglobin (HbA1c) >6.5% taking metformin at a daily dosage of 1,500–3,000 mg for ≥3 months. Patients were randomly assigned in a 1:1 ratio to receive either vildagliptin (50 mg) or remogliflozin (100 mg) twice daily for 90 days. The primary endpoint was a change in HbA1c levels from baseline to the end of 90 days whereas secondary endpoints were changes in lipid profile and weight. Results: The decrement in mean HbA1c levels was significantly higher in the remogliflozin group than in the vildagliptin group (−8.1% versus −2.4%; P"
    }
]